
Stewart‐Bluefarb syndrome: review of the literature and case report of chronic ulcer treatment with heparan sulphate ( Cacipliq 20®)
Author(s) -
Hayek Shady,
Atiyeh Bishara,
Zgheib Elias
Publication year - 2015
Publication title -
international wound journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.867
H-Index - 63
eISSN - 1742-481X
pISSN - 1742-4801
DOI - 10.1111/iwj.12074
Subject(s) - medicine , dapsone , dermatology , arteriovenous fistula , surgery , fistula , thalidomide , varicose ulcer , multiple myeloma
Stewart‐Bluefarb syndrome ( SBS ), also known as acroangiodermatitis or pseudo‐Kaposi, is a condition rarely encountered. It involves skin lesions that are clinically similar to Kaposi sarcoma but are histologically different, and are usually secondary to an underlying arteriovenous fistula. Treatment of this disease usually involves the correction of the underlying vascular abnormality, with the mainstay of therapy ranging from compression devices for venous stasis, limited oral medications (dapsone and erythromycin) and local wound care including topical steroids. Different methods of treatment showed varied success but none is ideal. We report a case of a lower extremity ulcer in a 22‐year‐old male recently diagnosed with SBS successfully treated with heparan sulphate (Cacipliq20®).